Priftin Approved by FDA for Latent Tuberculosis Infection Treatment

Article

The FDA today approved rifapentine (Priftin) in combination with isoniazid for a new indication for the treatment of latent tuberculosis infection.

The FDA today approved a new indication for rifapentine (Priftin) in combination with isoniazid (INH) for the treatment of latent tuberculosis infection (LTBI) in patients aged 2 and older at high risk of TB.

A New England Journal of Medicine study on LTBI revealed more patients completed the 12-dose once-weekly regimen of directly observed Priftin and INH than 9 months of daily self-administered INH, according to a press release from Sanofi. TB developed in 5 of 3074 patents taking both drugs, compared with 10 of 3074 patients who only took INH, according to Sanofi.

"Today's approval highlights the importance of public-private partnerships to address unmet public health challenges, with Sanofi working with the US Centers for Disease Control to study new opportunities to treat latent TB infection," said Paul Chew, MD, Sanofi’s global chief medical officer, in a press release. "The new approval for Priftin exemplifies the commitment to treating TB upheld by Sanofi for more than a half century."

Priftin, an antimycobacterial used in combination with 1 or more antituberculosis drugs for the treatment of active pulmonary TB, is currently only available in the United States.

Last year, 9 million people around the world became sick with TB, and 1.5 million died from the disease, according to the World Health Organization.

Related Videos
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.